HUTCHMED CEO weiguo Su Takes Medical Leave; Johnny Cheng Appointed as Acting CEO
London,UK – August 25,2025 – HUTCHMED (China) Limited (HCM,HCM.L) announced today that Weiguo Su, Chief Executive Officer, is taking a leave of absence to focus on his health. Effective instantly, Johnny Cheng, currently serving as Chief Financial Officer, has been appointed as Acting Chief Executive Officer.
The proclamation, initially reported by RTTNews, signals a temporary leadership shift for the pharmaceutical company focused on discovering, developing, and commercializing innovative medicines.https://www.rttnews.com/
Dan Eldar,Chairman and Non-executive Director of HUTCHMED,stated the Board’s full support for Dr. Su and wished him a swift recovery.”The Board expresses its full support for Dr Su and wishes him a speedy recovery,” Eldar commented.
Weiguo Su himself acknowledged the difficulty of the decision, emphasizing the need to prioritize his health at this time. “This has been a very arduous decision to make, but at this time my focus must be on my health,” Su saeid. “I would like to thank everyone for their support and look forward to being able to return to work quickly.”
Johnny Cheng’s appointment as Acting CEO ensures continuity in leadership during Dr.Su’s absence. HUTCHMED has not yet specified the duration of Dr. Su’s leave. investors and stakeholders will be closely watching for further updates regarding his health and potential return.
Keywords: HUTCHMED, Weiguo Su, Johnny Cheng, CEO, pharmaceutical company, leadership change, medical leave, HCM, HCM.L, China pharmaceutical, healthcare industry.